Načítá se...
Future perspectives in target-specific immunotherapies of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against acetylcholine receptors (AChR); antigen-specific CD4+ T cells, regulatory T cells (Tregs) and T helper (Th) 17+ cells are essential in antibody production. Target-specific therapeutic interventions should...
Uloženo v:
| Vydáno v: | Ther Adv Neurol Disord |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4643871/ https://ncbi.nlm.nih.gov/pubmed/26600875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615605700 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|